HIV and Ischemic Heart Disease

Journal of the American College of Cardiology

Volumn 69, Issue 1, 2017, Pages 73-82

  Vachiat, Ahmed ^a   McCutcheon, Keir ^a   Tsabedze, Nqoba ^a   Zachariah, Don ^a   Manga, Pravin ^a  

^a UNIVERSITY OF THE WITWATERSRAND   (South Africa)

Author keywords

acquired immunodeficiency syndrome; antiretroviral agents; atherosclerosis; coronary heart disease; drug interactions; myocardial infarction

Indexed keywords

ACETYLSALICYLIC ACID; ANTIRETROVIRUS AGENT; ATORVASTATIN; CHEMOKINE RECEPTOR CCR5 ANTAGONIST; CLOPIDOGREL; COBICISTAT; DARUNAVIR; EFAVIRENZ; ETRAVIRINE; FLUINDOSTATIN; HUMAN IMMUNODEFICIENCY VIRUS PROTEINASE INHIBITOR; INTEGRASE INHIBITOR; LOPINAVIR PLUS RITONAVIR; METHOTREXATE; MEVINOLIN; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; PITAVASTATIN; PRASUGREL; PRAVASTATIN; RITONAVIR; RITONAVIR PLUS TIPRANAVIR; ROSUVASTATIN; SIMVASTATIN; TICAGRELOR;

ACUTE CORONARY SYNDROME; ATHEROSCLEROSIS; BLOOD CLOTTING DISORDER; CARDIOVASCULAR RISK; CORONARY ARTERY DISEASE; DISEASE ASSOCIATION; DRUG ANTAGONISM; DRUG ELUTING STENT; DRUG POTENTIATION; DYSLIPIDEMIA; ENDOTHELIAL DYSFUNCTION; HEART MUSCLE REVASCULARIZATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; INCIDENCE; INFLAMMATION; ISCHEMIC CARDIOMYOPATHY; ISCHEMIC HEART DISEASE; PATHOGENESIS; PREVALENCE; PRIORITY JOURNAL; PROGNOSIS; REVIEW; RISK ASSESSMENT; RISK FACTOR; RISK REDUCTION; SEX DIFFERENCE; COMPLICATION; GLOBAL HEALTH; HIV INFECTIONS; HUMAN IMMUNODEFICIENCY VIRUS; MYOCARDIAL ISCHEMIA;

GLOBAL HEALTH; HIV; HIV INFECTIONS; HUMANS; INCIDENCE; MYOCARDIAL ISCHEMIA; PREVALENCE; RISK FACTORS;

EID: 85009070588     PISSN: 07351097     EISSN: 15583597     Source Type: Journal    
DOI: 10.1016/j.jacc.2016.09.979     Document Type: Review

References (85)

1. 1 World Health Organization. 10 facts on HIV/AIDS. Available at: http://www.who.int/features/factfiles/hiv/facts/en/. Accessed October 30, 2016.
2. 2 UNAIDS. HIV and AIDS estimates (2015). Available at: http://www.unaids.org/en/regionscountries/countries/southafrica. Accessed November 16, 2015.
3. 3 Lang, S., Boccara, F., Mary-Krause, M., et al. Epidemiology of coronary heart disease in HIV-infected versus uninfected individuals in developed countries. Arch Cardiovasc Dis 108 (2015), 206–215.
4. 4 Triant, V.A., Lee, H., Hadigan, C., et al. Increased acute myocardial infarction rates and cardiovascular risk factors among patients with human immunodeficiency virus disease. J Clin Endocrinol Metab 92 (2007), 2506–2512.
5. 5 Freiberg, M.S., Chang, C.C., Kuller, L.H., et al. HIV infection and the risk of acute myocardial infarction. JAMA Intern Med 173 (2013), 614–622.
6. 6 Wang, X., Chai, H., Yao, Q., et al. Molecular mechanisms of HIV protease inhibitor-induced endothelial dysfunction. J Acquir Immune Defic Syndr 44 (2007), 493–499.
7. 7 Worm, S.W., Sabin, C., Weber, R., et al. Risk of myocardial infarction in patients with HIV infection exposed to specific individual antiretroviral drugs from the 3 major drug classes: the data collection on adverse events of anti-HIV drugs (D:A:D) study. J Infect Dis 201 (2010), 318–330.
8. 8 Strategies for Management of Antiretroviral Therapy (SMART) Study Group. CD4+ count-guided interruption of antiretroviral treatment. N Engl J Med 355 (2006), 2283–2296.
9. 9 Manga, P., McCutcheon, K., Tsabedze, N., Vachiat, A., Zachariah, D., HIV and nonischemic heart disease. J Am Coll Cardiol 69 (2017), 83–91.
10. 10 Ingle, S.M., May, M.T., Gill, M.J., et al., for the Antiretroviral Therapy Cohort Collaboration. Impact of risk factors for specific causes of death in the first and subsequent years of antiretroviral therapy among HIV-infected patients. Clin Infect Dis 59 (2014), 287–297.
11. 11 Bozzette, S.A., Ake, C.F., Tam, H.K., et al. Cardiovascular and cerebrovascular events in patients treated for human immunodeficiency virus infection. N Engl J Med 348 (2003), 702–710.
12. 12 Mary-Krause, M., Cotte, L., Simon, A., et al., for the Clinical Epidemiology Group from the French Hospital Database. Increased risk of myocardial infarction with duration of protease inhibitor therapy in HIV-infected men. AIDS 17 (2003), 2479–2486.
13. 13 Currier, J.S., Taylor, A., Boyd, F., et al. Coronary heart disease in HIV-infected individuals. J Acquir Immune Defic Syndr 33 (2003), 506–512.
14. 14 Data Collection on Adverse Events of Anti-HIV Drugs (DAD) Study Group. Combination antiretroviral therapy and the risk of myocardial infarction. N Engl J Med 349 (2003), 1993–2003.
15. 15 Coplan, P.M., Nikas, A., Japour, A., et al. Incidence of myocardial infarction in randomized clinical trials of protease inhibitor-based antiretroviral therapy: an analysis of four different protease inhibitors. AIDS Res Hum Retroviruses 19 (2003), 449–455.
16. 16 Iloeje, U.H., Yuan, Y., L'Italien, G., et al. Protease inhibitor exposure and increased risk of cardiovascular disease in HIV-infected patients. HIV Med 6 (2005), 37–44.
17. 17 Lang, S., Mary-Krause, M., Cotte, L., et al., for the French Hospital Database on HIV-ANRS CO4. Increased risk of myocardial infarction in HIV-infected patients in France, relative to the general population. AIDS 24 (2010), 1228–1230.
18. 18 Durand, M., Sheehy, O., Baril, J.G., et al. Association between HIV infection, antiretroviral therapy, and risk of acute myocardial infarction: a cohort and nested case-control study using Quebec's public health insurance database. J Acquir Immune Defic Syndr 57 (2011), 245–253.
19. 19 Silverberg, M.J., Leyden, W.A., Xu, L., et al. Immunodeficiency and risk of myocardial infarction among HIV-positive individuals with access to care. J Acquir Immune Defic Syndr 65 (2014), 160–166.
20. 20 Paisible, A.L., Chang, C.C., So-Armah, K.A., et al. HIV infection, cardiovascular disease risk factor profile, and risk for acute myocardial infarction. J Acquir Immune Defic Syndr 68 (2015), 209–216.
21. 21 Klein, D.B., Leyden, W.A., Xu, L., et al. Declining relative risk for myocardial infarction among HIV-positive compared with HIV-negative individuals with access to care. Clin Infect Dis 60 (2015), 1278–1280.
22. 22 Julius, H., Basu, D., Ricci, E., et al. The burden of metabolic diseases amongst HIV positive patients on HAART attending The Johannesburg Hospital. Curr HIV Res 9 (2011), 247–252.
23. 23 Pearce, D., Ani, C., Espinosa-Silva, Y., et al. Comparison of in-hospital mortality from acute myocardial infarction in HIV sero-positive versus sero-negative individuals. Am J Cardiol 110 (2012), 1078–1084.
24. 24 Tseng, Z.H., Secemsky, E.A., Dowdy, D., et al. Sudden cardiac death in patients with human immunodeficiency virus infection. J Am Coll Cardiol 59 (2012), 1891–1896.
25. 25 Lifson, A.R., Neuhaus, J., Arribas, J.R., et al. Smoking-related health risks among persons with HIV in the Strategies for Management of Antiretroviral Therapy clinical trial. Am J Public Health 100 (2010), 1896–1903.
26. 26 DAD Study Group. Class of antiretroviral drugs and the risk of myocardial infarction. N Engl J Med 356 (2007), 1723–1735.
27. 27 Armah, K.A., Chang, C.C., Baker, J.V., et al., for the Veterans Aging Cohort Study (VACS) Project Team. Prehypertension, hypertension, and the risk of acute myocardial infarction in HIV-infected and -uninfected veterans. Clin Infect Dis 58 (2014), 121–129.
28. 28 Pasternak, A.O., de Bruin, M., Jurriaans, S., et al. Modest nonadherence to antiretroviral therapy promotes residual HIV-1 replication in the absence of virological rebound in plasma. J Infect Dis 206 (2012), 1443–1452.
29. 29 Lo, J., Looby, S.E., Wei, J., et al. Increased aldosterone among HIV-infected women with visceral fat accumulation. AIDS 23 (2009), 2366–2370.
30. 30 Estrada, V., Portilla, J., Dyslipidemia related to antiretroviral therapy. AIDS Rev 13 (2011), 49–56.
31. 31 Fishbein, G.A., Micheletti, R.G., Currier, J.S., et al. Atherosclerotic oxalosis in coronary arteries. Cardiovasc Pathol 17 (2008), 117–123.
32. 32 Eugenin, E.A., Morgello, S., Klotman, M.E., et al. Human immunodeficiency virus (HIV) infects human arterial smooth muscle cells in vivo and in vitro: implications for the pathogenesis of HIV-mediated vascular disease. Am J Pathol 172 (2008), 1100–1111.
33. 33 Hulten, E., Mitchell, J., Scally, J., et al. HIV positivity, protease inhibitor exposure and subclinical atherosclerosis: a systematic review and meta-analysis of observational studies. Heart 95 (2009), 1826–1835.
34. 34 D'Ascenzo, F., Cerrato, E., Calcagno, A., et al. High prevalence at computed coronary tomography of non-calcified plaques in asymptomatic HIV patients treated with HAART: a meta-analysis. Atherosclerosis 240 (2015), 197–204.
35. 35 Stein, J.H., Currier, J.S., Hsue, P.Y., Arterial disease in patients with human immunodeficiency virus infection: what has imaging taught us?. J Am Coll Cardiol Img 7 (2014), 515–525.
36. 36 McComsey, G.A., O'Riordan, M., Hazen, S.L., et al. Increased carotid intima media thickness and cardiac biomarkers in HIV infected children. AIDS 21 (2007), 921–927.
37. 37 Kuller, L.H., Tracy, R., Belloso, W., et al., for the INSIGHT SMART Study Group. Inflammatory and coagulation biomarkers and mortality in patients with HIV infection. PLoS Med, 5, 2008, e203.
38. 38 Triant, V.A., Meigs, J.B., Grinspoon, S.K., Association of C-reactive protein and HIV infection with acute myocardial infarction. J Acquir Immune Defic Syndr 51 (2009), 268–273.
39. 39 Tenorio, A.R., Zheng, Y., Bosch, R.J., et al. Soluble markers of inflammation and coagulation but not T-cell activation predict non-AIDS-defining morbid events during suppressive antiretroviral treatment. J Infect Dis 210 (2014), 1248–1259.
40. 40 Fitch, K.V., Srinivasa, S., Abbara, S., et al. Noncalcified coronary atherosclerotic plaque and immune activation in HIV-infected women. J Infect Dis 208 (2013), 1737–1746.
41. 41 So-Armah, K., Freiberg, M.S., Cardiovascular disease risk in an aging HIV population: not just a question of biology. Curr Opin HIV AIDS 9 (2014), 346–354.
42. 42 Fernández-Montero, J.V., Barreiro, P., de Mendoza, C., et al. Hepatitis C virus coinfection independently increases the risk of cardiovascular disease in HIV-positive patients. J Viral Hepat 23 (2016), 47–52.
43. 43 Borissoff, J.I., ten Cate, H., From neutrophil extracellular traps release to thrombosis: an overshooting host-defense mechanism?. J Thromb Haemost 9 (2011), 1791–1794.
44. 44 de Gaetano Donati, K., Rabagliati, R., Iacoviello, L., et al. HIV infection, HAART, and endothelial adhesion molecules: current perspectives. Lancet Infect Dis 4 (2004), 213–222.
45. 45 Graham, S.M., Rajwans, N., Jaoko, W., et al. Endothelial activation biomarkers increase after HIV-1 acquisition: plasma vascular cell adhesion molecule-1 predicts disease progression. AIDS 27 (2013), 1803–1813.
46. 46 Torriani, F.J., Komarow, L., Parker, R.A., et al., for the ACTG 5152s Study Team. Endothelial function in human immunodeficiency virus-infected antiretroviral-naive subjects before and after starting potent antiretroviral therapy: The ACTG (AIDS Clinical Trials Group) Study 5152s. J Am Coll Cardiol 52 (2008), 569–576.
47. 47 Seigneur, M., Constans, J., Blann, A., et al. Soluble adhesion molecules and endothelial cell damage in HIV infected patients. Thromb Haemost 77 (1997), 646–649.
48. 48 Ford, E.S., Greenwald, J.H., Richterman, A.G., et al. Traditional risk factors and D-dimer predict incident cardiovascular disease events in chronic HIV infection. AIDS 24 (2010), 1509–1517.
49. 49 Boccara, F., Lang, S., Meuleman, C., et al. HIV and coronary heart disease: time for a better understanding. J Am Coll Cardiol 61 (2013), 511–523.
50. 50 Becker, A.C., Libhaber, E., Sliwa, K., et al. Antiphospholipid antibodies in black South Africans with HIV and acute coronary syndromes: prevalence and clinical correlates. BMC Res Notes, 4, 2011, 379.
51. 51 Karmochkine, M., Ankri, A., Calvez, V., et al. Plasma hypercoagulability is correlated to plasma HIV load. Thromb Haemost 80 (1998), 208–209.
52. 52 O'Brien, M., Montenont, E., Hu, L., et al. Aspirin attenuates platelet activation and immune activation in HIV-1-infected subjects on antiretroviral therapy: a pilot study. J Acquir Immune Defic Syndr 63 (2013), 280–288.
53. 53 Hsue, P.Y., Giri, K., Erickson, S., et al. Clinical features of acute coronary syndromes in patients with human immunodeficiency virus infection. Circulation 109 (2004), 316–319.
54. 54 Boccara, F., Mary-Krause, M., Teiger, E., et al. Acute coronary syndrome in human immunodeficiency virus-infected patients: characteristics and 1 year prognosis. Eur Heart J 32 (2011), 41–50.
55. 55 Becker, A.C., Sliwa, K., Stewart, S., et al. Acute coronary syndromes in treatment-naive black South Africans with human immunodeficiency virus infection. J Interv Cardiol 23 (2010), 70–77.
56. 56 Manga, P., HIV and heart disease in Africa. J Am Coll Cardiol 66 (2015), 586–588.
57. 57 Law, M.G., Friis-Møller, N., El-Sadr, W.M., et al., for the D:A:D Study Group. The use of the Framingham equation to predict myocardial infarctions in HIV-infected patients: comparison with observed events in the D:A:D Study. HIV Med 7 (2006), 218–230.
58. 58 Mooney, S., Tracy, R., Osler, T., et al. Elevated biomarkers of inflammation and coagulation in patients with HIV are associated with higher Framingham and VACS risk index scores. PLoS One, 10, 2015, e0144312.
59. 59 Friis-Møller, N., Ryom, L., Smith, C., et al., for the D:A:D study group. An updated prediction model of the global risk of cardiovascular disease in HIV-positive persons: The Data-collection on Adverse Effects of Anti-HIV Drugs (D:A:D) study. Eur J Prev Cardiol 23 (2016), 214–223.
60. 60 Calza, L., Manfredi, R., Colangeli, V., et al. Two-year treatment with rosuvastatin reduces carotid intima-media thickness in HIV type 1-infected patients receiving highly active antiretroviral therapy with asymptomatic atherosclerosis and moderate cardiovascular risk. AIDS Res Hum Retroviruses 29 (2013), 547–556.
61. 61 Lo, J., Lu, M.T., Ihenachor, E.J., et al. Effects of statin therapy on coronary artery plaque volume and high-risk plaque morphology in HIV-infected patients with subclinical atherosclerosis: a randomised, double-blind, placebo-controlled trial. Lancet HIV 2 (2015), e52–e63.
62. 62 Nolte, J.E., Neumann, T., Manne, J.M., et al. Cost-effectiveness analysis of coronary artery disease screening in HIV-infected men. Eur J Prev Cardiol 21 (2014), 972–979.
63. 63 Helleberg, M., May, M.T., Ingle, S.M., et al. Smoking and life expectancy among HIV-infected individuals on antiretroviral therapy in Europe and North America. AIDS 29 (2015), 221–229.
64. 64 Petoumenos, K., Worm, S., Reiss, P., et al., for the D:A:D Study Group. Rates of cardiovascular disease following smoking cessation in patients with HIV infection: results from the D:A:D study. HIV Med 12 (2011), 412–421.
65. 65 Longenecker, C.T., Eckard, A.R., McComsey, G.A., Statins to improve cardiovascular outcomes in treated HIV infection. Curr Opin Infect Dis 29 (2016), 1–9.
66. 66 Aberg, J.A., Gallant, J.E., Ghanem, K.G., et al. Primary care guidelines for the management of persons infected with HIV: 2013 update by the HIV Medicine Association of the Infectious Diseases Society of America. Clin Infect Dis 58 (2014), 1–10.
67. 67 Negredo, E., Moltó, J., Puig, J., et al. Ezetimibe, a promising lipid-lowering agent for the treatment of dyslipidaemia in HIV-infected patients with poor response to statins. AIDS 20 (2006), 2159–2164.
68. 68 Aberg, J.A., Zackin, R.A., Brobst, S.W., et al. A randomized trial of the efficacy and safety of fenofibrate versus pravastatin in HIV-infected subjects with lipid abnormalities: AIDS Clinical Trials Group Study 5087. AIDS Res Hum Retroviruses 21 (2005), 757–767.
69. 69 Gilbert, J.M., Fitch, K.V., Grinspoon, S.K., HIV-related cardiovascular disease, statins, and the REPRIEVE trial. Top Antivir Med 23 (2015), 146–149.
70. 70 Malvestutto, C.D., Ma, Q., Morse, G.D., et al. Lack of pharmacokinetic interactions between pitavastatin and efavirenz or darunavir/ritonavir. J Acquir Immune Defic Syndr 67 (2014), 390–396.
71. 71 Sandler, N.G., Zhang, X., Bosch, R.J., et al. Sevelamer does not decrease lipopolysaccharide or soluble CD14 levels but decreases soluble tissue factor, low-density lipoprotein (LDL) cholesterol, and oxidized LDL cholesterol levels in individuals with untreated HIV infection. J Infect Dis 210 (2014), 1549–1554.
72. 72 INSIGHT START Study Group. Initiation of antiretroviral therapy in early asymptomatic HIV infection. N Engl J Med 373 (2015), 795–807.
73. 73 World Health Organization. Consolidated guidelines on HIV prevention, diagnosis, treatment and care for key populations: 2016 update. Available at: http://apps.who.int/iris/bitstream/10665/246200/1/9789241511124-eng.pdf?ua=1. Accessed October 29, 2016.
74. 74 Wang, Z.Y., Chen, M., Zhu, L.L., et al. Pharmacokinetic drug interactions with clopidogrel: updated review and risk management in combination therapy. Ther Clin Risk Manag 11 (2015), 449–467.
75. 75 Egan, G., Hughes, C.A., Ackman, M.L., Drug interactions between antiplatelet or novel oral anticoagulant medications and antiretroviral medications. Ann Pharmacother 48 (2014), 734–740.
76. 76 Daali, Y., Ancrenaz, V., Bosilkovska, M., et al. Ritonavir inhibits the two main prasugrel bioactivation pathways in vitro: a potential drug-drug interaction in HIV patients. Metabolism 60 (2011), 1584–1589.
77. 77 Zhou, D., Andersson, T.B., Grimm, S.W., In vitro evaluation of potential drug-drug interactions with ticagrelor: cytochrome P450 reaction phenotyping, inhibition, induction, and differential kinetics. Drug Metab Dispos 39 (2011), 703–710.
78. 78 Ren, X., Trilesskaya, M., Kwan, D.M., et al. Comparison of outcomes using bare metal versus drug-eluting stents in coronary artery disease patients with and without human immunodeficiency virus infection. Am J Cardiol 104 (2009), 216–222.
79. 79 Boccara, F., Teiger, E., Cohen, A., et al. Percutaneous coronary intervention in HIV infected patients: immediate results and long term prognosis. Heart 92 (2006), 543–544.
80. 80 D'Ascenzo, F., Cerrato, E., Appleton, D., et al., for the Percutaneous coronary intervention and surgical revascularization in HIV Database (PHD) Study Investigators. Prognostic indicators for recurrent thrombotic events in HIV-infected patients with acute coronary syndromes: use of registry data from 12 sites in Europe, South Africa and the United States. Thromb Res 134 (2014), 558–564.
81. 81 Blyth, D.F., Buckels, N.J., Sewsunker, R.R., et al. An experience with cardiopulmonary bypass in HIV-infected patients. Cardiovasc J S Afr 17 (2006), 178–185.
82. 82 Lorgis, L., Cottenet, J., Molins, G., et al. Outcomes after acute myocardial infarction in HIV-infected patients: analysis of data from a French nationwide hospital medical information database. Circulation 127 (2013), 1767–1774.
83. 83 Agüero, F., Castel, M.A., Cocchi, S., et al. An update on heart transplantation in human immunodeficiency virus-infected patients. Am J Transplant 16 (2016), 21–28.
84. 84 D'Ascenzo, F., Cerrato, E., Biondi-Zoccai, G., et al. Acute coronary syndromes in human immunodeficiency virus patients: a meta-analysis investigating adverse event rates and the role of antiretroviral therapy. Eur Heart J 33 (2012), 875–880.
85. 85 Remick, J., Georgiopoulou, V., Marti, C., et al. Heart failure in patients with human immunodeficiency virus infection: epidemiology, pathophysiology, treatment, and future research. Circulation 129 (2014), 1781–1789.